
1. mol microbiol. 2015 jul;97(2):381-95. doi: 10.1111/mmi.13035. epub 2015 may 20.

balancing drug resistance growth rates via compensatory mutations the
plasmodium falciparum chloroquine resistance transporter.

petersen i(1)(2), gabryszewski sj(1), johnston gl(1)(3), dhingra sk(1)(4), ecker 
a(1), lewis re(1), de almeida mj(1), straimer j(1), henrich pp(1), palatulan
e(1), johnson dj(1), coburn-flynn o(1), sanchez c(2), lehane am(1), lanzer m(2), 
fidock da(1)(5).

author information: 
(1)department microbiology immunology, columbia university medical center,
new york, ny, 10032, usa.
(2)hygiene institut, abteilung parasitologie, universitätsklinikum heidelberg,
69120, heidelberg, germany.
(3)school international public affairs, columbia university, new york, ny,
10027, usa.
(4)department biological sciences, binghamton university, binghamton, ny,
13902, usa.
(5)division infectious diseases, department medicine, columbia university
medical center, new york, ny, 10032, usa.

the widespread use chloroquine treat plasmodium falciparum infections has
resulted selection dissemination variant haplotypes primary 
resistance determinant pfcrt. haplotypes encountered drug pressure and
within-host competition wild-type drug-sensitive parasites. examine these
selective forces vitro, genetically engineered p. falciparum express
geographically diverse pfcrt haplotypes. variant alleles philippines
(ph1 ph2, differ solely c72s mutation) conferred moderate
gain chloroquine resistance reduction growth rates vitro. the
two, ph2 showed higher ic50 values, contrasting reduced growth. furthermore,
a highly mutated pfcrt allele cambodia (cam734) conferred moderate
chloroquine resistance enhanced growth rates, tested wild-type
pfcrt co-culture competition assays. three alleles mediated
cross-resistance amodiaquine, antimalarial drug widely used africa. each
allele, along globally prevalent dd2 7g8 alleles, rendered parasites
more susceptible lumefantrine, partner drug used leading first-line
artemisinin-based combination therapy. data reveal ongoing region-specific 
evolution pfcrt impacts drug susceptibility relative fitness in
settings mixed infections, raise important considerations optimal
agents treat chloroquine-resistant malaria.

© 2015 john wiley & sons ltd.

doi: 10.1111/mmi.13035 
pmcid: pmc4511469
pmid: 25898991  [indexed medline]

